Seraph 100—A new extracorporeal device to decrease elevated sFlt‐1 in preeclamptic plasma?
- 11 December 2024
- journal article
- research article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 29 (2) , 325-326
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Therapeutic Plasma Exchange in Early-Onset Preeclampsia: A 7-Year Monocentric ExperienceJournal of Clinical Medicine, 2023
- Therapeutic plasma exchange and dextran‐sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restrictionJournal of Clinical Apheresis, 2021
- Preeclampsia—Pathophysiology and Clinical PresentationsJACC, 2020
- Heparin 2.0: A New Approach to the Infection CrisisBlood Purification, 2020
- LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trialEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2018
- Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in PreeclampsiaJournal of the American Society of Nephrology, 2016
- Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected PreeclampsiaNew England Journal of Medicine, 2016
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004